-
Teclistamab, sold
under the
brand name Tecvayli, is a
human bispecific monoclonal antibody used for the
treatment of
relapsed and
refractory multiple...
-
public domain. "Janssen
Marks First Approval Worldwide for
Tecvayli (
teclistamab) with EC
Authorisation of First-in-class
Bispecific Antibody for the...
- antibodies. The
first drug in this
class approved for
multiple myeloma is
teclistamab, but its use is
reserved for
people in the
later stages of the disease...
- (talquetamab) for the
treatment of relapsed/refractory MM (Janssen)
Tecvayli (
teclistamab) for the
treatment of relapsed/refractory MM (Janssen)
Tepezza (teprotumumab)...
-
Clinical trial number NCT04722146 for "A Multi-arm
Phase 1b
Study of
Teclistamab With
Other Anticancer Therapies in Parti****nts With
Multiple Myeloma"...
-
Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumabâ€
Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab...
-
Naxitamab L01FX22
Loncastuximab tesirine L01FX23
Tisotumab vedotin L01FX24
Teclistamab L01FX25
Mosunetuzumab L01FX26
Mirvetuximab soravtansine L01FX27 Epcoritamab...
-
approved by the US FDA: emicizumab, amivantamab, tebentafusp, faricimab,
teclistamab, mosunetuzumab, epcoritamab, glofitamab.
Among the bsAb
programs currently...
-
govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zenocutuzumab...
-
withdrawn for
commercial reasons.
Others include amivantamab, blinatumomab,
teclistamab, and emicizumab.
Since 2000, the
therapeutic market for
monoclonal antibodies...
